WHAT IS CLAIMED IS:

1. A topical skin formulation, wherein the topical formulation is an oil-in-water emulsion, comprising:
about 0.5% to about 1.5% of a pharmaceutically acceptable salt of ruxolitinib on a free base basis by weight of the formulation;
an aqueous component;
an oil component;
an non-ionic emulsifier component; and
a pharmaceutically acceptable acid.

2. The topical skin formulation of claim 1, wherein the pharmaceutically acceptable acid is selected from phosphoric acid, citric acid, and lactic acid.

3. The topical skin formulation according to claim 2, wherein the phosphoric acid is present in an amount of about 0.1% to about 0.5%, or about 0.05% to about 0.15%, or about 0.15% to about 0.25%, by weight of the formulation.

4. The topical skin formulation according to claim 2, wherein the citric acid or lactic acid is present in an amount of about 1% to about 5% by weight of the formulation.

5. The topical skin formulation according to any one of claims 1-4, wherein
(i) the oil component comprises from about 10% to about 30%, or about 15% to about 30%, or about 20% to about 25%, by weight of the formulation;
(ii) the non-ionic emulsifier component is present in an amount of about 2% to about 6%, or about 3% to about 5%, by weight of the formulation; and/or
(iii) the aqueous component comprises from about 40% to about 90%, or about 60% to about 80%, by weight of the formulation.

6. The topical skin formulation according to any one of claims 1-5, wherein

(a)the oil component comprises: (i) one or more substances independently selected from petrolatums, fatty alcohols, mineral oils, triglycerides, and silicone oils; or (ii) white petrolatum, cetyl alcohol, stearyl alcohol, light mineral oil, medium chain triglycerides, and dimethicone 350;

(b) the non-ionic emulsifier component comprises: (i) one or more glyceryl fatty esters and one or more sorbitan fatty esters; or (ii) glyceryl stearate and polysorbate 20; and/or

(c) the aqueous component comprises: (i) water and one or more substances independently selected from C_{1-3} alkyl parabens, alkylene glycols, polyalkylene glycols; polysaccharides, and chelating agents; or (ii) water, one or more C_{1-3} alkyl parabens, one or more alkylene glycols, one or more polyalkylene glycols; one or more polysaccharides, and one or more chelating agents; or (iii) water, methyl paraben, propyl paraben, propylene glycol, polyethylene glycol 200, xanthan gum, and edetate disodium.

7. The topical skin formulation according to any one of claims 1-6, wherein the oil component comprises, by weight of the formulation:

(i) about 3% to about 5% of one or more mineral oils;
about 6% to about 8% of one or more petrolatums;
about 4% to about 6% of one or more fatty alcohols;
about 0.5% to about 1.5% of one of more silicone oils; and
about 4% to about 6% of one or more trigylcerides; or

(ii) about 3% to about 5% of light mineral oil;
about 6% to about 8% of white petrolatum;
about 4% to about 6% of a mixture of cetyl alcohol and stearyl alcohol;
about 0.5% to about 1.5% of dimethicone 350; and
about 4% to about 6% of medium chain trigylcerides; or

(iii) about 4% of light mineral oil;
about 7% of white petrolatum;
about 3% of cetyl alcohol;

about 1.75% of stearyl alcohol;
about 1% of dimethicone 350; and
about 5% of medium chain trigylcerides.

8. The topical skin formulation according to any one of claims 1-7, wherein the aqueous component comprises, by weight of the formulation:

(i) about 40% to about 60% water;
about 10 to about 20% of one or more alkylene glycols;
about 5% to about 10% of one or more polyalkylene glycols;
about 0.03% to about 0.2% of one or more C_{1-3} alkyl parabens;
about 0.3% to about 0.5% of one or more polysaccharides; and
about 0.01% to about 0.1% of one or more chelating agents; or

(ii) about 45% to about 50% water;
about 13 to about 17% of one or more alkylene glycols;
about 6% to about 8% of one or more polyalkyelene glycols;
about 0.05% to about 0.2% of one or more C_{1-3} alkyl parabens;
about 0.3% to about 0.5% of one or more polysaccharides; and
about 0.03% to about 0.07% of one or more chelating agents; or

(iii) about 45% to about 50% water;
about 14 to about 16% of one or more alkylene glycols;
about 6% to about 8% of one or more polyalkyelene glycols;
about 0.05% to about 0.2% of one or more C_{1-3} alkyl parabens;
about 0.3% to about 0.5% of one or more polysaccharides; and
about 0.04% to about 0.06% of one or more chelating agents; or

(iv) about 45% to about 50% water;
about 13 to about 17% of propylene glycol;
about 6% to about 8% of polyethylene glycol 200;
about 0.05% to about 0.15% of methyl paraben;
about 0.01% to about 0.1% of propyl paraben;
about 0.3% to about 0.5% of xanthan gum;
about 0.03% to about 0.07% of edetate disodium; or

(v) about 45% to about 50% water;
about 14 to about 16% of propylene glycol;
about 6% to about 8% of polyethylene glycol 200;
about 0.08% to about 0.12% of methyl paraben;
about 0.03% to about 0.08% of propyl paraben;
about 0.3% to about 0.5% of xanthan gum; and
about 0.04% to about 0.06% of edetate disodium; or

(vi) about 45% to about 50% water;
about 15% of propylene glycol;
about 7% of polyethylene glycol 200;
about 0.1% of methyl paraben;
about 0.05% of propyl paraben;
about 0.4% of xanthan gum; and
about 0.05% of edetate disodium.

9. The topical skin formulation according to any one of claims 1-8, wherein the pharmaceutically acceptable salt of ruxolitinib is ruxolitinib phosphate, ruxolitinib chloride, ruxolitinib mesylate, ruxolitinib maleate, ruxolitinib sulfate, ruxolitinib ediyslate, ruxolitinib napadisylate, ruxolitinib acesulfmate, ruxolitinib oxalate, ruxolitinib L-tartrate, ruxolitinib hydrobromide, and ruxolitinib hydroiodate.

10. The topical skin formulation according to any one of claims 1-9, wherein the pharmaceutically acceptable salt of ruxolitinib is present in an amount of about 0.75%, or about 1.5%, by weight of the formulation on a free base basis.

11. The topical skin formulation according to any one of claims 1-10, further comprising about 0.4% to about 0.6% of phenoxyethanol.

12. The topical skin formulation according to claim 1, wherein the topical skin formulation comprises (by weight of the formulation):

(i) about 10% to about 30% of the oil component;

about 40% to about 90% of the aqueous component;
about 0.5% to about 1.5% of the pharmaceutically acceptable salt of ruxolitinib; and
about 0.1% to about 0.5% of phosphoric acid; or

(ii) about 10% to about 30% of the oil component;
about 40% to about 90% of the aqueous component;
about 0.5% to about 1.5% of the pharmaceutically acceptable salt of ruxolitinib; and
about 0.05% to about 0.15% of phosphoric acid; or

(iii) about 15% to about 30% of the oil component;
about 50% to about 80% of the aqueous component;
about 0.5% to about 1.5% of the pharmaceutically acceptable salt of ruxolitinib; and
about 0.1% to about 0.5% of phosphoric acid; or

(iv) about 15% to about 30% of the oil component;
about 50% to about 80% of the aqueous component;
about 0.5% to about 1.5% of the pharmaceutically acceptable salt of ruxolitinib; and
about 0.05% to about 0.15% of phosphoric acid; or

(v) about 20% to about 27% of the oil component;
about 60% to about 80% of the aqueous component;
about 0.5% to about 1.5% of the pharmaceutically acceptable salt of ruxolitinib; and
about 0.1% to about 0.5% of phosphoric acid; or

(vi) about 20% to about 27% of the oil component;
about 60% to about 80% of the aqueous component;
about 0.5% to about 1.5% of the pharmaceutically acceptable salt of ruxolitinib; and
about 0.05% to about 0.15% of phosphoric acid.

13. The topical skin formulation according to claim 12, wherein the aqueous component comprises about 40% to about 60% of water by weight of the formulation.

14. The topical skin formulation according to any one of claims 1-13, wherein the pH of the formulation is about 2.6 to about 3.3.

15. The topical skin formulation according to any one of claims 1-14, wherein the formulation is a cream or a solubilized cream.

16. Use of the topical skin formulation according to any one of claims 1-15 in the manufacture of a medicament for the treatment of a skin disorder in a patient in need thereof.

17. The use of claim 16, wherein the skin disorder is: (i) atopic dermatitis; or (ii) psoriasis; or (iii) non-segmental vitiligo; or (iv) skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization; or (v) a bullous skin disorder; or (vi) hidradenitis suppurativa; or (vii) lichen planus; or (viii) alopecia; or (ix) alopecia areata; or (x) frontal fibrosing alopecia; or (xi) lichen planopilaris; or (xii) seborrheic dermatitis.

18. The use of claim 17, wherein the bullous skin disorder is pemphigus vulgaris (PV) or bullous pemphigoid (BP).

19. The topical skin formulation according to any one of claims 1-15, for use in treatment of a skin disorder in a patient in need thereof.